Oculis (OCS) Scheduled to Post Earnings on Thursday

Oculis (NASDAQ:OCS) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Oculis to post earnings of ($0.52) per share for the quarter.

Oculis (NASDAQ:OCS) last released its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). The firm had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Stock Down 0.2 %

OCS stock traded down $0.03 during trading hours on Tuesday, reaching $17.56. 88,046 shares of the stock were exchanged, compared to its average volume of 36,273. The company has a market cap of $711.18 million, a price-to-earnings ratio of -9.02 and a beta of -0.16. The firm’s 50-day moving average is $13.62 and its 200-day moving average is $12.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. Oculis has a 12 month low of $9.60 and a 12 month high of $18.00.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $29.20.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.